Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma
Starting soon · Phase 2
Conditions studied: Gastric Cancer (GC), AFP Gastric or Gastroesophageal Junction Adenocarcinoma
In brief
Alpha-fetoprotein-producing gastric cancer (AFP-positive gastric cancer, AFP-GC), a rare and highly aggressive subtype of gastric cancer, accounts for 1.3% to 15% of all gastric cancer cases. Its clinical features are significantly different from those of common gastric cancer. Not only does it show abnormally elevated serum AFP levels, but it also has a stronger angiogenic ability, a higher rate of distant metastasis, and a poorer prognosis even after a upfront R0 surgery, making it a challenging problem in the field of gastric cancer treatment. Notably, patients with AFP-positive gastric cancer have a relatively low sensitivity to the traditional standard regimens. There is an urgent need to explore targeted treatment strategies to break through the efficacy bottleneck. Combination of sintilimab, bevacizumab and XELOX/SOX for initially unresectable AFP-positive gastric/esophagogastric junction adenocarcinoma could be a novel therapeutic strategy to increase response rate and therapeutic efficacy. This study is a multi-center, single-arm phase 2 clinical trial to evaluate efficacy, tolerability and safety of perioperative sintilimab in combination with bevacizumab and XELOX/SOX in initially unresectable AFP-positive gastric/esophagogastric junction adenocarcinoma.
Key facts
- Study ID
- NCT07515625
- Run by
- Fudan University
- People needed
- 46
- Starts
- 2026-04-01
- Expected to finish
- 2029-04-01
- Last updated by the study team
- 2026-04-07
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Signed informed consent;
- Patients age 18-75 years;
- Histologically CT/MRI confirmed cT3-4N+M0/1 gastric or GEJ adenocarcinoma; (M1 only includes type I liver metastasis of gastric cancer, according to the "Chinese Expert Consensus on Liver Metastasis of Gastric Cancer");
- Serum AFP levels > 2× upper limit of normal or AFP-positive by IHC staining;
- Adequate organ function
- ECOG 0-1, no surgery contraindications;
- Expected survival ≥3 months;
You may not qualify if…
- HER2-positive status: IHC 3+, or IHC 2+/FISH+
- Prior chemotherapy, radiotherapy, anti-PD-1/PD-L1 therapy, surgery for gastric cancer;
- Signs of other distant metastases (e.g., peritoneal, lung, bone, supraclavicular lymph, etc.)
- Significant cardiovascular disease
- -Current treatment with anti-viral therapy or HBV
- Pregnancy or breastfeeding
- History of malignancy within 5 years prior to screening
- Present or history of any autoimmune disease or immune deficiency;
- There are active gastric and duodenal ulcers, ulcerative colitis and other gastrointestinal diseases, or active bleeding in unresectable tumors.
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.